Company Description

Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets.

The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain.

It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.

Exicure, Inc.

Country	United States
Founded	2011
Industry	Biotechnology
Sector	Healthcare
Employees	7
CEO	Paul Kang

Contact Details

Address: 2430 N. Halsted St. Chicago, Illinois 60614 United States
Phone	847-673-1700
Website	exicuretx.com

Stock Details

Ticker Symbol	XCUR
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001698530
CUSIP Number	30205M101
ISIN Number	US30205M2008
Employer ID	81-5333008
SIC Code	2834

Key Executives

Name	Position
Paul Kang	Chief Executive Officer and Director
Jiyoung Hwang	Chief Financial Officer and Director
Joshua Miller	Chief Accounting Officer
Bart Anderson	Senior Director of Research & Development

Latest SEC Filings

Date	Type	Title
Apr 22, 2024	8-K	Current Report
Apr 1, 2024	NT 10-K	Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Mar 4, 2024	SC 13D/A	[Amend] General statement of acquisition of beneficial ownership
Feb 5, 2024	8-K	Current Report
Jan 16, 2024	8-K	Current Report
Dec 1, 2023	8-K	Current Report
Nov 28, 2023	8-K	Current Report
Nov 14, 2023	NT 10-Q	Notification of inability to timely file Form 10-Q or 10-QSB
Oct 6, 2023	8-K	Current Report
Sep 27, 2023	8-K	Current Report

View All SEC Filings